Differential Effects of Inhibitory and Stimulatory Anti-Her2 Monoclonal Antibodies on Akt/Erk Signaling Pathways Publisher Pubmed



Soltantoyeh T¹ ; Bahadori T² ; Hosseinighatar R¹ ; Khoshnoodi J¹ ; Roohi A¹ ; Mobini M¹ ; Golsazshirazi F¹ ; Jedditehrani M² ; Amiri MM¹ ; Shokri F^{1, 2} Show Affiliations
Source: Asian Pacific Journal of Cancer Prevention Published:2018

Abstract

Objective: Homo- and heterodimerization of the receptor tyrosine kinase HER2 hyperactivate several downstream signaling pathways, leading to uncontrolled growth and proliferation of tumor cells. Anti-HER2 monoclonal antibodies (mAbs) may induce different effects on HER2 dimerization and signaling. Methods: The effect of two inhibitory (2A8, 1T0) and one stimulatory (1H9) anti-HER2 mAbs either alone or in combination with trastuzumab was investigated on AKT and ERK signaling pathways and HER2 degradation in a human breast cancer cell line (BT-474) by Western blotting. Result: While 1H9 mAb had no significant effect on AKT and ERK signaling pathways, 1T0 and 2A8 mAbs inhibited phosphorylation of both pathways. Combination of 1T0 mAb with trastuzumab resulted in significant synergistic inhibition of both pathways and HER2 degradation, much more potently than the combination of trastuzumab and pertuzumab. Conclusion: Our data indicate that anti-HER2 mAbs may induce different signaling pathways depending on their effect on tumor cell growth and proliferation. The significant inhibition of ERK and AKT phosphorylation by 1T0 alone or particularly in combination with trastuzumab suggests its potential therapeutic application for targeted immunotherapy of HER2 overexpressing malignancies. © 2018 Asian Pacific Organization for Cancer Prevention.